ORGO Stock — Organogenesis Holdings Inc.: Cash, EV, Pipeline

Share price

$1.42

Market cap

$182.7M

Cash

$46.1M

Enterprise value

$136.6M

Balance sheet

Cash	$46.1M
Debt	$0.0M
Net cash	$46.1M
Enterprise value	$136.6M
Basic shares	128.7M shares
Fully diluted shares	176.0M shares
Fully diluted market cap	$250.0M
Cash per share	$0.36

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ORGO daily closes…

Loading price history…

Pipeline assets

ReNu

Phase 3 · Active Modality: regenerative medicine (cryopreserved amniotic suspension allograft)

Aliases amniotic suspension allograft (ASA)

Indications

Symptomatic knee osteoarthritis (Phase 3)
Symptoms associated with hip OA (planning) (Discovery)

Catalysts

— 2027-04-24

Status note Two Phase 3 RCTs completed. Rolling BLA initiated December 2025 and completed April 24, 2026; FDA accepted for review June 2026 with PDUFA date April 24, 2027.

Dermagraft

Approved · Active Modality: regenerative medicine (living cell-based skin substitute)

Indications

Chronic and acute wounds (Approved)

Status note Pre-launch manufacturing activities underway at the Smithfield, Rhode Island biomanufacturing facility ahead of commercial relaunch; facility FDA approval required for manufacturing.

Apligraf

Approved · Active Modality: regenerative medicine (living cell-based skin substitute)

Partnerships Novartis Pharma AG (trademark and domain name rights license)

Indications

Wounds (Approved)

Status note Marketed wound care product; existing products hold PMA approval or 510(k) clearance.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07510412	Not disclosed	Recruiting	Sponsor	Organogenesis	—	Venous Leg Ulcers	—
NCT06618612	Not disclosed	Recruiting	Sponsor	Organogenesis	—	Diabetic Foot Ulcer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Organogenesis on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	550,000	no change	0.19%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ORGO — Organogenesis Holdings Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders